{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:08:48Z","timestamp":1784304528986,"version":"3.55.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["1801"],"award-info":[{"award-number":["1801"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"name":"JSPS","award":["21H02376"],"award-info":[{"award-number":["21H02376"]}]},{"name":"JSPS","award":["22K15483"],"award-info":[{"award-number":["22K15483"]}]},{"name":"JSPS","award":["23K15362"],"award-info":[{"award-number":["23K15362"]}]},{"name":"Australian National Health and Medical Research Council","award":["#1194036"],"award-info":[{"award-number":["#1194036"]}]},{"name":"Australian National Health and Medical Research Council","award":["#1173871"],"award-info":[{"award-number":["#1173871"]}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23wm0125008"],"award-info":[{"award-number":["JP23wm0125008"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP223fa627005"],"award-info":[{"award-number":["JP223fa627005"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23wm0125008"],"award-info":[{"award-number":["JP23wm0125008"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP223fa627005"],"award-info":[{"award-number":["JP223fa627005"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23wm0125008"],"award-info":[{"award-number":["JP23wm0125008"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Due to the synchronous circulation of seasonal influenza viruses and severe acute respiratory coronavirus 2 (SARS-CoV-2) which causes coronavirus disease 2019 (COVID-19), there is need for routine vaccination for both COVID-19 and influenza to reduce disease severity. Here, we prepared individual WPVs composed of formalin-inactivated SARS-CoV-2 WK 521 (Ancestral strain; Co WPV) or influenza virus [A\/California\/07\/2009 (X-179A) (H1N1) pdm; Flu WPV] to produce a two-in-one Co\/Flu WPV. Serum analysis from vaccinated mice revealed that a single dose of Co\/Flu WPV induced antigen-specific neutralizing antibodies against both viruses, similar to those induced by either type of WPV alone. Following infection with either virus, mice vaccinated with Co\/Flu WPV showed no weight loss, reduced pneumonia and viral titers in the lung, and lower gene expression of proinflammatory cytokines, as observed with individual WPV-vaccinated. Furthermore, a pentavalent vaccine (Co\/qFlu WPV) comprising of Co WPV and quadrivalent influenza vaccine (qFlu WPV) was immunogenic and protected animals from severe COVID-19. These results suggest that a single dose of the two-in-one WPV provides efficient protection against SARS-CoV-2 and influenza virus infections with no evidence of vaccine interference in mice. We propose that concomitant vaccination with the two-in-one WPV can be useful for controlling both diseases.<\/jats:p>","DOI":"10.1038\/s41598-024-54421-1","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T12:04:44Z","timestamp":1708430684000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Immunogenicity and protective efficacy of a co-formulated two-in-one inactivated whole virus particle COVID-19\/influenza vaccine"],"prefix":"10.1038","volume":"14","author":[{"given":"Chimuka","family":"Handabile","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marumi","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Sekiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Kawakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamiko","family":"Kawahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minako","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Toba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihito","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuko","family":"Orba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon Y.","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise C.","family":"Rowntree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi H. O.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Shingai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Ogasawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Kedzierska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"key":"54421_CR1","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41579-021-00642-4","volume":"19","author":"M Koutsakos","year":"2021","unstructured":"Koutsakos, M., Wheatley, A. K., Laurie, K., Kent, S. J. & Rockman, S. Influenza lineage extinction during the COVID-19 pandemic?. Nat. Rev. Microbiol. 19, 741\u2013742 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"54421_CR2","doi-asserted-by":"publisher","first-page":"00296","DOI":"10.1183\/23120541.00296-2020","volume":"6","author":"G Young","year":"2020","unstructured":"Young, G. et al. Rapid decline of seasonal influenza during the outbreak of COVID-19. ERJ Open Res. 6, 00296\u201302020 (2020).","journal-title":"ERJ Open Res."},{"key":"54421_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-23440-1","volume":"12","author":"L Feng","year":"2021","unstructured":"Feng, L. et al. Impact of COVID-19 outbreaks and interventions on influenza in China and the United States. Nat. Commun. 12, 1\u20138 (2021).","journal-title":"Nat. Commun."},{"key":"54421_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-20314-w","volume":"12","author":"QS Huang","year":"2021","unstructured":"Huang, Q. S. et al. Impact of the COVID-19 nonpharmaceutical interventions on influenza and other respiratory viral infections in New Zealand. Nat. Commun. 12, 1\u20137 (2021).","journal-title":"Nat. Commun."},{"key":"54421_CR5","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1038\/s41467-022-29402-5","volume":"13","author":"V Dhanasekaran","year":"2022","unstructured":"Dhanasekaran, V. et al. Human seasonal influenza under COVID-19 and the potential consequences of influenza lineage elimination. Nat. Commun. 13, 1721 (2022).","journal-title":"Nat. Commun."},{"key":"54421_CR6","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1093\/infdis\/jiaa570","volume":"222","author":"H Lei","year":"2020","unstructured":"Lei, H. et al. Nonpharmaceutical interventions used to control COVID-19 reduced seasonal influenza transmission in China. J. Infect. Dis. 222, 1780\u20131783 (2020).","journal-title":"J. Infect. Dis."},{"key":"54421_CR7","doi-asserted-by":"publisher","first-page":"e1612","DOI":"10.1016\/S2214-109X(22)00358-8","volume":"10","author":"ST Ali","year":"2022","unstructured":"Ali, S. T. et al. Prediction of upcoming global infection burden of influenza seasons after relaxation of public health and social measures during the COVID-19 pandemic: A modelling study. Lancet Glob. Health 10, e1612\u2013e1622 (2022).","journal-title":"Lancet Glob. Health"},{"key":"54421_CR8","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.ijid.2022.08.002","volume":"122","author":"SS Lee","year":"2022","unstructured":"Lee, S. S., Viboud, C. & Petersen, E. Understanding the rebound of influenza in the post COVID-19 pandemic period holds important clues for epidemiology and control. Int. J. Infect. Dis. 122, 1002\u20131004 (2022).","journal-title":"Int. J. Infect. Dis."},{"key":"54421_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12985-021-01594-0","volume":"18","author":"B Alosaimi","year":"2021","unstructured":"Alosaimi, B. et al. Influenza co-infection associated with severity and mortality in COVID-19 patients. Virol. J. 18, 1\u20139 (2021).","journal-title":"Virol. J."},{"key":"54421_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-020-00451-w","volume":"6","author":"L Bao","year":"2021","unstructured":"Bao, L. et al. Sequential infection with H1N1 and SARS-CoV-2 aggravated COVID-19 pathogenesis in a mammalian model, and co-vaccination as an effective method of prevention of COVID-19 and influenza. Signal Transduct. Target. Ther. 6, 1\u20138 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"54421_CR11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41422-021-00473-1","volume":"31","author":"L Bai","year":"2021","unstructured":"Bai, L. et al. Coinfection with influenza a virus enhances SARS-CoV-2 infectivity. Cell. Res. 31, 395\u2013403 (2021).","journal-title":"Cell. Res."},{"key":"54421_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/vaccines10060976","volume":"10","author":"D Pascucci","year":"2022","unstructured":"Pascucci, D. et al. Flu and COVID-19 vaccination: What happens to the flu shot when the campaigns overlap? Experience from a large Italian research hospital. Vaccines 10, 1\u20139 (2022).","journal-title":"Vaccines"},{"key":"54421_CR13","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMc2204560","volume":"386","author":"RK Leuchter","year":"2022","unstructured":"Leuchter, R. K., Jackson, N. J., Mafi, J. N. & Sarkisian, C. A. Association between Covid-19 vaccination and influenza vaccination rates. N. Engl. J. Med. 386, 2531\u20132532 (2022).","journal-title":"N. Engl. J. Med."},{"key":"54421_CR14","unstructured":"SAGE Working Group on Influenza. Coadministration of seasonal inactivated influenza and COVID-19 vaccines: Interim guidance. (World Health Organization 2021)."},{"key":"54421_CR15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3390\/vaccines11010109","volume":"11","author":"D Focosi","year":"2023","unstructured":"Focosi, D. From Co-Administration to Co-Formulation: The cace for new vaccines against COVID-19 and other respiratory viruses. Vaccines 11, 109 (2023).","journal-title":"Vaccines"},{"key":"54421_CR16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jconrel.2020.08.013","volume":"327","author":"VM Chauhan","year":"2020","unstructured":"Chauhan, V. M., Zhang, H., Dalby, P. A. & Aylott, J. W. Advancements in the co-formulation of biologic therapeutics. J. Control. Release 327, 397\u2013405 (2020).","journal-title":"J. Control. Release"},{"key":"54421_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41541-022-00478-w","volume":"7","author":"Q Ye","year":"2022","unstructured":"Ye, Q. et al. Rational development of a combined mRNA vaccine against COVID-19 and influenza. NPJ Vaccines 7, 84 (2022).","journal-title":"NPJ Vaccines"},{"key":"54421_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/ane.13550","volume":"145","author":"J Finsterer","year":"2022","unstructured":"Finsterer, J. Neurological side effects of SARS-CoV-2 vaccinations. Acta. Neurol. Scand. 145, 5\u20139 (2022).","journal-title":"Acta. Neurol. Scand."},{"key":"54421_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-19936-5","volume":"12","author":"T Akaishi","year":"2022","unstructured":"Akaishi, T., Onodera, T., Takahashi, T., Harigae, H. & Ishii, T. Reports of acute adverse events in mRNA COVID-19 vaccine recipients after the first and second doses in Japan. Sci. Rep. 12, 1\u20136 (2022).","journal-title":"Sci. Rep."},{"key":"54421_CR20","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41591-021-01630-0","volume":"28","author":"M Patone","year":"2022","unstructured":"Patone, M. et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat. Med. 28, 410\u2013422 (2022).","journal-title":"Nat. Med."},{"key":"54421_CR21","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1093\/cid\/ciab152","volume":"73","author":"C Boikos","year":"2021","unstructured":"Boikos, C. et al. Relative effectiveness of adjuvanted trivalent inactivated influenza vaccine versus egg-derived quadrivalent inactivated influenza vaccines and high-dose trivalent influenza vaccine in preventing influenza-related medical encounters in US adults \u2265 65 year. Clin. Infect. Dis. 73, 816\u2013823 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"54421_CR22","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1080\/21645515.2016.1242539","volume":"13","author":"AL Stuurman","year":"2017","unstructured":"Stuurman, A. L., Marano, C., Bunge, E. M., De Moerlooze, L. & Shouval, D. Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines\u2014A systematic review. Hum. Vaccin. Immunother. 13, 724\u2013736 (2017).","journal-title":"Hum. Vaccin. Immunother."},{"key":"54421_CR23","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1473-3099(20)30555-7","volume":"21","author":"AS Bandyopadhyay","year":"2021","unstructured":"Bandyopadhyay, A. S. et al. Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: A randomised open-label, multicentre, phase 3, non-inferiority trial. Lancet Infect. Dis. 21, 559\u2013568 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"54421_CR24","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.vaccine.2017.01.015","volume":"35","author":"Y Xing","year":"2017","unstructured":"Xing, Y., Schmitt, H. J., Arguedas, A. & Yang, J. Tick-borne encephalitis in China: A review of epidemiology and vaccines. Vaccine 35, 1227\u20131237 (2017).","journal-title":"Vaccine"},{"key":"54421_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0008142","volume":"14","author":"BLC Moreira","year":"2020","unstructured":"Moreira, B. L. C., Gimenez, A. P. L., Inagaki, J. M. F. & Raboni, S. M. Inactivated rabies vaccines: Standardization of an in vitro assay for residual viable virus detection. PLoS Negl. Trop. Dis. 14, 1\u201315 (2020).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"54421_CR26","doi-asserted-by":"publisher","first-page":"e2074","DOI":"10.1002\/rmv.2074","volume":"29","author":"A Sabbaghi","year":"2019","unstructured":"Sabbaghi, A., Miri, S. M., Keshavarz, M., Zargar, M. & Ghaemi, A. Inactivation methods for whole influenza vaccine production. Rev. Med. Virol. 29, e2074 (2019).","journal-title":"Rev. Med. Virol."},{"key":"54421_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/978-3-662-45024-6_2","volume-title":"Vaccine: Analysis Strategies, Principles, and Control","author":"B Sanders","year":"2015","unstructured":"Sanders, B., Koldijk, M. & Schuitemaker, H. Inactivated viral vaccines. In Vaccine: Analysis Strategies, Principles, and Control (eds Sanders, B. et al.) 45\u201380 (Springer, 2015)."},{"key":"54421_CR28","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.vaccine.2019.01.086","volume":"37","author":"J Herrera-Rodriguez","year":"2019","unstructured":"Herrera-Rodriguez, J., Signorazzi, A., Holtrop, M., de Vries-Idema, J. & Huckriede, A. Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production. Vaccine 37, 1630\u20131637 (2019).","journal-title":"Vaccine"},{"key":"54421_CR29","doi-asserted-by":"publisher","first-page":"108906","DOI":"10.1016\/j.intimp.2022.108906","volume":"109","author":"H Kouhpayeh","year":"2022","unstructured":"Kouhpayeh, H. & Ansari, H. Adverse events following COVID-19 vaccination: A systematic review and meta-analysis. Int. Immunopharmacol. 109, 108906 (2022).","journal-title":"Int. Immunopharmacol."},{"key":"54421_CR30","doi-asserted-by":"publisher","first-page":"5356","DOI":"10.1016\/j.vaccine.2022.07.021","volume":"40","author":"W Shenyu","year":"2022","unstructured":"Shenyu, W. et al. Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (CoronaVac) co-administered with an inactivated quadrivalent influenza vaccine: A randomized, open-label, controlled study in healthy adults aged 18 to 59 years in China. Vaccine 40, 5356\u20135365 (2022).","journal-title":"Vaccine"},{"key":"54421_CR31","doi-asserted-by":"publisher","first-page":"e1010891","DOI":"10.1371\/journal.ppat.1010891","volume":"18","author":"BY Chua","year":"2022","unstructured":"Chua, B. Y. et al. Immunization with inactivated whole virus particle influenza virus vaccines improves the humoral response landscape in cynomolgus macaques. PLoS Pathog. 18, e1010891 (2022).","journal-title":"PLoS Pathog."},{"key":"54421_CR32","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1016\/j.vaccine.2019.02.057","volume":"37","author":"T Sekiya","year":"2019","unstructured":"Sekiya, T. et al. Inactivated whole virus particle vaccine with potent immunogenicity and limited IL-6 induction is ideal for influenza. Vaccine 37, 2158\u20132166 (2019).","journal-title":"Vaccine"},{"key":"54421_CR33","doi-asserted-by":"publisher","first-page":"e2304139120","DOI":"10.1073\/pnas.2304139120","volume":"120","author":"K Uemura","year":"2023","unstructured":"Uemura, K. et al. 2-Thiouridine is a broad-spectrum antiviral nucleoside analogue against positive-strand RNA viruses. Proc. Natl. Acad. Sci. U.S.A 120, e2304139120 (2023).","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"54421_CR34","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","volume":"26","author":"DM Del Valle","year":"2020","unstructured":"Del Valle, D. M. et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 26, 1636\u20131643 (2020).","journal-title":"Nat. Med."},{"key":"54421_CR35","doi-asserted-by":"publisher","first-page":"5798","DOI":"10.1016\/j.vaccine.2022.08.036","volume":"40","author":"J Fraiman","year":"2022","unstructured":"Fraiman, J. et al. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. Vaccine 40, 5798\u20135805 (2022).","journal-title":"Vaccine"},{"key":"54421_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.807","author":"F Yasmin","year":"2023","unstructured":"Yasmin, F. et al. Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia. Immun. Inflamm. Dis. https:\/\/doi.org\/10.1002\/iid3.807 (2023).","journal-title":"Immun. Inflamm. Dis."},{"key":"54421_CR37","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s12276-023-00999-x","volume":"55","author":"J Lee","year":"2023","unstructured":"Lee, J., Woodruff, M. C., Kim, E. H. & Nam, J. H. Knife\u2019s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines. Exp. Mol. Med. 55, 1305\u20131313. https:\/\/doi.org\/10.1038\/s12276-023-00999-x (2023).","journal-title":"Exp. Mol. Med."},{"key":"54421_CR38","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","volume":"182","author":"H Wang","year":"2020","unstructured":"Wang, H. et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell 182, 713-721.e9 (2020).","journal-title":"Cell"},{"issue":"369","key":"54421_CR39","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1126\/science.abc1932","volume":"1979","author":"Q Gao","year":"2020","unstructured":"Gao, Q. et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 1979(369), 77\u201381 (2020).","journal-title":"Science"},{"key":"54421_CR40","doi-asserted-by":"publisher","first-page":"102054","DOI":"10.1016\/j.isci.2021.102054","volume":"24","author":"S Mohandas","year":"2021","unstructured":"Mohandas, S. et al. Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model. Iscience 24, 102054 (2021).","journal-title":"Iscience"},{"key":"54421_CR41","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.3390\/vaccines9111266","volume":"9","author":"STI Pavel","year":"2021","unstructured":"Pavel, S. T. I. et al. Development of an inactivated vaccine against sars COV-2. Vaccines 9, 1266 (2021).","journal-title":"Vaccines"},{"key":"54421_CR42","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1016\/j.vaccine.2021.05.065","volume":"39","author":"M Shingai","year":"2021","unstructured":"Shingai, M. et al. Potent priming by inactivated whole influenza virus particle vaccines is linked to viral RNA uptake into antigen presenting cells. Vaccine 39, 3940\u20133951 (2021).","journal-title":"Vaccine"},{"key":"54421_CR43","doi-asserted-by":"publisher","first-page":"804","DOI":"10.3390\/vaccines10050804","volume":"10","author":"C Handabile","year":"2022","unstructured":"Handabile, C. et al. Inactivated whole virus particle influenza vaccine induces anti-neuraminidase antibodies that may contribute to cross-protection against heterologous virus infection. Vaccines 10, 804 (2022).","journal-title":"Vaccines"},{"key":"54421_CR44","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1016\/S0140-6736(21)02329-1","volume":"398","author":"R Lazarus","year":"2021","unstructured":"Lazarus, R. et al. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): A multicentre, randomised, controlled, phase 4 trial. Lancet 398, 2277\u20132287 (2021).","journal-title":"Lancet"},{"key":"54421_CR45","doi-asserted-by":"publisher","first-page":"5322","DOI":"10.1016\/j.vaccine.2022.07.033","volume":"40","author":"H Chen","year":"2022","unstructured":"Chen, H. et al. Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiority, open-label, randomized, controlled, phase 4 trial. Vaccine 40, 5322\u20135332 (2022).","journal-title":"Vaccine"},{"key":"54421_CR46","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S2213-2600(21)00409-4","volume":"10","author":"S Toback","year":"2022","unstructured":"Toback, S. et al. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: An exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Respir. Med. 10, 167\u2013179 (2022).","journal-title":"Lancet Respir. Med."},{"key":"54421_CR47","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S2213-2600(21)00557-9","volume":"10","author":"R Izikson","year":"2022","unstructured":"Izikson, R. et al. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged \u226565 years: A phase 2, randomised, open-label study. Lancet Respir. Med. 10, 392\u2013402 (2022).","journal-title":"Lancet Respir. Med."},{"key":"54421_CR48","doi-asserted-by":"publisher","first-page":"376","DOI":"10.4049\/jimmunol.2100421","volume":"207","author":"WE Matchett","year":"2021","unstructured":"Matchett, W. E. et al. Cutting Edge: Nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity. J. Immunol. 207, 376\u2013379 (2021).","journal-title":"J. Immunol."},{"key":"54421_CR49","doi-asserted-by":"publisher","first-page":"e162282","DOI":"10.1172\/JCI162282","volume":"132","author":"T Dangi","year":"2022","unstructured":"Dangi, T. et al. Improved control of SARS-CoV-2 by treatment with a nucleocapsid-specific monoclonal antibody. J. Clin. Investig. 132, e162282 (2022).","journal-title":"J. Clin. Investig."},{"key":"54421_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/v13112137","volume":"13","author":"M Ohno","year":"2021","unstructured":"Ohno, M. et al. Abnormal blood coagulation and kidney damage in aged hamsters infected with severe acute respiratory syndrome coronavirus 2. Viruses 13, 1\u201318 (2021).","journal-title":"Viruses"},{"key":"54421_CR51","doi-asserted-by":"publisher","first-page":"e01578","DOI":"10.1128\/jvi.01578-21","volume":"96","author":"K Cao","year":"2022","unstructured":"Cao, K. et al. A single vaccine protects against SARS-CoV-2 and influenza virus in mice. J. Virol. 96, e01578-e1621 (2022).","journal-title":"J. Virol."},{"key":"54421_CR52","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1016\/S0140-6736(21)02758-6","volume":"398","author":"SSA Karim","year":"2021","unstructured":"Karim, S. S. A. & Karim, Q. A. Omicron SARS-CoV-2 variant: A new chapter in the COVID-19 pandemic. Lancet 398, 2126\u20132128 (2021).","journal-title":"Lancet"},{"key":"54421_CR53","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41586-022-04399-5","volume":"602","author":"JM Carre\u00f1o","year":"2022","unstructured":"Carre\u00f1o, J. M. et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 602, 682\u2013688 (2022).","journal-title":"Nature"},{"issue":"16","key":"54421_CR54","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews, N. et al. Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern. N. Engl. J. Med. 386(16), 1532\u20131546 (2022).","journal-title":"N. Engl. J. Med."},{"key":"54421_CR55","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41591-022-01715-4","volume":"28","author":"PR Wratil","year":"2022","unstructured":"Wratil, P. R. et al. Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. Nat. Med. 28, 496\u2013503 (2022).","journal-title":"Nat. Med."},{"key":"54421_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-021-00411-7","volume":"6","author":"M Brinkkemper","year":"2021","unstructured":"Brinkkemper, M. et al. A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern. NPJ Vaccin. 6, 1\u20136 (2021).","journal-title":"NPJ Vaccin."},{"key":"54421_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-19967-4","volume":"11","author":"MD Fahlberg","year":"2020","unstructured":"Fahlberg, M. D. et al. Cellular events of acute, resolving or progressive COVID-19 in SARS-CoV-2 infected non-human primates. Nat. Commun. 11, 1\u201314 (2020).","journal-title":"Nat. Commun."},{"key":"54421_CR58","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ajpath.2013.10.004","volume":"184","author":"H Ogiwara","year":"2014","unstructured":"Ogiwara, H. et al. Histopathological evaluation of the diversity of cells susceptible to H5N1 virulent avian influenza virus. Am. J. Pathol. 184, 171\u2013183 (2014).","journal-title":"Am. J. Pathol."},{"key":"54421_CR59","first-page":"1","volume":"2","author":"R Kono","year":"2022","unstructured":"Kono, R. & Takagi, A. An attenuated vaccinia vaccine encoding the severe acute respiratory syndrome coronavirus-2 spike protein elicits broad and durable immune responses and protects cynomolgus macaques and enzyme 2 transgenic mice from severe acute respiratory syndrome coronavirus-2 and its variants. Front. Microbiol. 2, 1\u201318 (2022).","journal-title":"Front. Microbiol."},{"key":"54421_CR60","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1016\/j.vaccine.2022.05.045","volume":"40","author":"M Shiohara","year":"2022","unstructured":"Shiohara, M., Suzuki, S., Shichinohe, S., Ishigaki, H. & Nakayama, M. Inactivated whole influenza virus particle vaccines induce neutralizing antibodies with an increase in immunoglobulin gene subclones of B-lymphocytes in cynomolgus macaques. Vaccine 40, 4026\u20134037 (2022).","journal-title":"Vaccine"},{"key":"54421_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: Open source software for digital pathology image analysis. Sci. Rep. https:\/\/doi.org\/10.1038\/s41598-017-17204-5 (2017).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-54421-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-54421-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-54421-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T13:22:25Z","timestamp":1708435345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-54421-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["54421"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-54421-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,20]]},"assertion":[{"value":"2 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M. Endo, T. Nishimura, M. Okumura, S. Toba, and A. Sato belong to the companies.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4204"}}